Director and CEO
Mr. Hoffmann is entirely dedicated to Network Immunology's systems approach to treating disease and optimizing health. Realizing the immense untapped value in the network approach to understanding immuno-regulation, Hoffmann co-founded Network Immunology with Chief Scientist, Dr. Geoffrey W. Hoffmann in 2003. In 2007, Hoffmann was appointed Manager of Business Development. In 2009, at a key juncture in the Company’s history, he was appointed President and CEO. Since then he has been a major driver behind the Company's development and expansion.
He has contributed to the assembling of a team with the scientific expertise, business acumen and financial and developmental resources necessary to advance
Network Immunology’s platform immuno-therapeutic product, AbstimX™. With the help of this outstanding team,
Hoffmann has grown Network Immunology from an idea-stage startup, to a significant industry contender with the potential for tremendous success. The
Company has developed a leading-edge patented technology and product, AbstimX™, and the stage of development
has crossed a critical tipping point, as this immuno-therapeutic is now on the verge of entering human clinical trials.
As the central communications hub of the company, Mr. Hoffmann is working with Management, the Board of Directors and the Scientific Advisory Board to advance AbstimX™ through the clinic to the stage of commercialization. Mr. Hoffmann ensures the Company continues to take steps toward increasing shareholder value in various ways, including taking steps toward profitable commercial licensing agreements that management is confident will provide robust capital gains and returns on investment for Network Immunology Inc. shareholders.